Key Highlights

  • Edwards Lifesciences (NYSE:EW) grew net sales 10.5% to USD 1,715.5 million, yet absorbed a USD 220.2 million impairment, largely tied to an in-process R&D asset written down.
  • PROCEPT BioRobotics (NASDAQ:PRCT) lifted Revenue 18% to USD 98.3 million, although its loss rose to USD 26.5 million, or USD 0.46 a share, from USD 21.4 million.
  • STAAR Surgical (NASDAQ:STAA) recorded USD 83.4 million of net sales, a 12.0% decline, since the comparison period contained USD 25.9 million from a postponed China shipment.
  • LeMaitre Vascular (NASDAQ:LMAT) raised net sales 11% to USD 67.97 million, but diluted EPS slipped to USD 0.65 from USD 0.75, measured against a retention tax Credit recorded a year earlier.

Edwards Lifesciences (NYSE:EW): The USD 220.2 Million Impairment Against 10.5% Sales Growth

Edwards Lifesciences (NYSE:EW) submitted its Quarterly Report on November 4, 2026, covering the period that ended September 30. Sales totaled USD 1,715.5 million, a 10.5% gain, transcatheter mitral and tricuspid sales rose 44.3%, reaching USD 209.5 million, while the transcatheter aortic valve line grew 8.0% to USD 1,241.6 million. Against the USD 220.2 million impairment stands a USD 40.0 million charge from a year before. Certain litigation matters produced a net insurance recovery of USD 12.7 million, versus USD 90.4 million of expense a year earlier. Income attributable to the company climbed to USD 307.5 million, up from USD 291.1 million, and diluted EPS came in at USD 0.53 compared with USD 0.50. Gross Margin reached about 78.5%, against 77.8%, a ratio our own calculation derived from gross profit. In the nine-month view, diluted EPS dropped to USD 1.61 from USD 1.67; management pins that on greater tax expense and impairment charges. Tariff uncertainty is named as a risk, and the extract reviewed holds no guidance figures. Cash and equivalents were USD 3,110.8 million.

PROCEPT BioRobotics (NASDAQ:PRCT): Revenue Up 18% While Tariff Refunds Flatter the Margin

PROCEPT BioRobotics (NASDAQ:PRCT) released its quarterly report on November 4, 2026. Its AquaBeam and HYDROS robotic systems deliver water-jet Aquablation therapy for benign prostatic hyperplasia, and 1,095 units are installed worldwide. Revenue hit USD 98.3 million, an 18% increase. Handpieces and consumables jumped 22% to USD 60.8 million, service revenue advanced 51%, and system sales and leases edged up only 4% to USD 29.2 million. Gross margin landed at 66%, compared with 65% a year earlier, and the filing credits mostly USD 3.2 million of tariff refunds, which makes the underlying trend harder to read. Operating spending climbed 20% to USD 92.5 million, and the operating loss widened 18% to USD 27.4 million. On the balance sheet, USD 218.4 million sat in cash and equivalents, with USD 52.0 million drawn on the Loan facility. A putative securities class action, filed July 24, 2026, along with a related derivative action filed September 15, 2026, appear in the disclosures. Management says any outcome or loss estimate is out of reach for now, and the sections reviewed contain no outlook.

STAAR Surgical (NASDAQ:STAA): The 12.0% Sales Drop Traces to One Delayed China Shipment

STAAR Surgical (NASDAQ:STAA) put its fiscal Q3 numbers on file on November 4, 2026. Its Implantable Collamer Lenses sit inside the eye without replacing the natural lens. Sales for the fiscal quarter closing October 2, 2026 reached USD 83.4 million, down from USD 94.7 million, because the 2025 period included USD 25.9 million booked from the delayed December China Shipment. Excluding that amount, the filing says sales would have risen 21.1% from a base of USD 68.8 million, with EMEA up 31% and the Americas up 14%. Earnings were USD 5.6 million (USD 0.11 a diluted share), against USD 8.9 million (USD 0.18) in the prior period. The gross margin slid to 70.9% from 82.2%, and the company does not foresee hitting its 75% goal in 2026, while expecting better results in the fourth quarter. Manufacturing costs, freight, tariffs and inventory provisions were blamed by the company. Available-for-sale cash and investments came to USD 206.4 million, and in September the board announced a USD 50.0 million buyback authorization. No shares were bought back during the quarter, and neither a price reference nor a numeric outlook appears.

LeMaitre Vascular (NASDAQ:LMAT): Sales Up 11%, but EPS Lower Against a Prior Tax Credit

LeMaitre Vascular (NASDAQ:LMAT) reported third-quarter results on November 4, 2026. It supplies devices and implants for peripheral vascular disease, mainly to vascular surgeons. Net sales climbed 11% to USD 67.97 million, or 12% on an organic basis, with price contributing 7% and units 5%. Diluted EPS of USD 0.65 compared with USD 0.75, because the 2025 quarter contained a non-recurring employee retention tax credit, and the company says an adjusted measure would be 5% higher once that item is excluded. Gross margin stood at 71.7%: a 360-basis-point decline on a reported basis, yet a 90-basis-point gain once adjusted. Operating profit landed at USD 17.7 million, down from USD 20.3 million. October brought a USD 19.2 million payment from the company to B. Braun for vascular Assets that generated USD 9.4 million of 2025 sales, and roughly USD 150,000 of fourth-quarter sales is expected from them. For the full year, the range is USD 274.8 million up to USD 276.8 million in sales and USD 2.77 to USD 2.82 in EPS. The quarterly USD 0.25 Dividend goes out December 3, 2026, and eligibility is set by the November 19, 2026 record date. Cash and marketable securities were about USD 390 million.

Where Things Stand

Single events can mislead when they land in the base period or in one quarter, and these four results illustrate that. Edwards Lifesciences (NYSE:EW) recorded a USD 220.2 million impairment alongside 10.5% sales growth, so the charge alone does not point to softer demand. STAAR Surgical (NASDAQ:STAA) reports a 12.0% drop mainly because the prior year held a single USD 25.9 million shipment, and its underlying trend was up 21.1%. LeMaitre Vascular (NASDAQ:LMAT) shows lower EPS due to a prior-year tax credit. PROCEPT BioRobotics (NASDAQ:PRCT) is distinct, since its margin gain came mostly from tariff refunds while its loss widens. Watch Edwards for tariffs and tax, STAAR for margin recovery, LeMaitre for how it absorbs the B. Braun assets, and PROCEPT for the class action.